BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:T3D Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies T3D Therapeutics's drugs run\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06964230-724@assetmemo.bio
DTSTAMP:20261121T005710Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:T3D-959: Phase 2/3 readout est. (NCT06964230)
DESCRIPTION:T3D-959\, phase 2/3\, Alzheimer's Disease.\nStudy: A Phase 2b/3
  Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease
  Subjects\nEstimated primary completion: April 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/t3d-959#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06964230
URL:https://assetmemo.bio/drug/t3d-959#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
